OGNNYSEPharmaceutical PreparationsFiscal year ends December 31
Organon & Co.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$13.75−0.01 (-0.07%)
Close on Oct 19, 2026
- Market cap
- $3.72B
- P/E (TTM)
- 17.6
- Dividend yield
- 2.47%
Organon & Co. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Nexplanon/Implanon NXT | $921.00M | $963.00M | $830.00M | $834.00M | $769.00M | $680.00M | $787.00M | 14.8% | -4.4% |
| Zetia | $342.00M | $317.00M | $322.00M | $370.00M | $378.00M | $482.00M | $590.00M | 5.5% | +7.9% |
| Other | $338.00M | $328.00M | $319.00M | $326.00M | $357.00M | $379.00M | $238.00M | 5.4% | +3.0% |
| Atozet | $324.00M | $473.00M | $519.00M | $457.00M | $458.00M | $453.00M | $391.00M | 5.2% | -31.5% |
| Other Non-Opiod Pain, Bone and Dermatology | $301.00M | $295.00M | $275.00M | $273.00M | $286.00M | $278.00M | $214.00M | 4.8% | +2.0% |
| Arcoxia | $265.00M | $270.00M | $257.00M | $241.00M | $244.00M | $258.00M | $288.00M | 4.3% | -1.9% |
| Follistim AQ | $264.00M | $237.00M | $262.00M | $229.00M | $237.00M | $193.00M | $241.00M | 4.2% | +11.4% |
| Nasonex | $262.00M | $276.00M | $266.00M | $260.00M | $206.00M | $218.00M | $293.00M | 4.2% | -5.1% |
| Singulair | $252.00M | $359.00M | $404.00M | $411.00M | $413.00M | $462.00M | $698.00M | 4.1% | -29.8% |
| Renflexis | $251.00M | $274.00M | $278.00M | $226.00M | $186.00M | $135.00M | $96.00M | 4.0% | -8.4% |
| Hadlima | $228.00M | $142.00M | $44.00M | $19.00M | $13.00M | $0 | – | 3.7% | +60.6% |
| Cozaar/Hyzaar | $219.00M | $243.00M | $281.00M | $323.00M | $357.00M | $386.00M | $442.00M | 3.5% | -9.9% |
| Other Women's Health | $174.00M | $158.00M | $147.00M | $138.00M | $206.00M | $270.00M | $173.00M | 2.8% | +10.1% |
| Emgality | $174.00M | $107.00M | $0 | $0 | – | – | – | 2.8% | +62.6% |
| Dulera | $153.00M | $203.00M | $194.00M | $180.00M | $190.00M | $222.00M | $217.00M | 2.5% | -24.6% |
| Diprospan | $150.00M | $139.00M | $91.00M | $122.00M | $125.00M | $118.00M | $102.00M | 2.4% | +7.9% |
| Fosamax | $143.00M | $151.00M | $159.00M | $152.00M | $175.00M | $180.00M | $197.00M | 2.3% | -5.3% |
| Vtama | $128.00M | $12.00M | $0 | $0 | – | – | – | 2.1% | +966.7% |
| Marvelon/Mercilon | $127.00M | $134.00M | $134.00M | $110.00M | $98.00M | $95.00M | – | 2.0% | -5.2% |
| Other Cardiovascular | $126.00M | $133.00M | $139.00M | $146.00M | $191.00M | $239.00M | $134.00M | 2.0% | -5.3% |
| Clarinex | $123.00M | $127.00M | $136.00M | $125.00M | $111.00M | $130.00M | $142.00M | 2.0% | -3.1% |
| Propecia | $118.00M | $111.00M | $125.00M | $125.00M | $136.00M | $129.00M | $131.00M | 1.9% | +6.3% |
| Ganirelix Acetate Injection | $101.00M | $109.00M | $110.00M | $123.00M | $111.00M | – | – | 1.6% | -7.3% |
| Vytorin | $100.00M | $108.00M | $129.00M | $130.00M | $164.00M | $182.00M | $285.00M | 1.6% | -7.4% |
| Ontruzant | $99.00M | $141.00M | $155.00M | $122.00M | $126.00M | $115.00M | $83.00M | 1.6% | -29.8% |
| Proscar | $97.00M | $95.00M | $97.00M | $101.00M | $117.00M | $176.00M | $203.00M | 1.6% | +2.1% |
| Nuva Ring | $91.00M | $115.00M | $176.00M | $219.00M | $191.00M | $236.00M | $879.00M | 1.5% | -20.9% |
| Other | $82.00M | $115.00M | $121.00M | $146.00M | $200.00M | $107.00M | $102.00M | 1.3% | -28.7% |
| Brenzys | $80.00M | $77.00M | $73.00M | $75.00M | $63.00M | $74.00M | $72.00M | 1.3% | +3.9% |
| Jada | $74.00M | $61.00M | $43.00M | $20.00M | $3.00M | – | – | 1.2% | +21.3% |
| Other Respiratory | $52.00M | $53.00M | $64.00M | $61.00M | $89.00M | $118.00M | $25.00M | 0.8% | -1.9% |
| Other Biosimilars | $33.00M | $28.00M | $43.00M | – | $49.00M | $6.00M | $0 | 0.5% | +17.9% |
| Rosuzet | $24.00M | $49.00M | $70.00M | $71.00M | $68.00M | $130.00M | $120.00M | 0.4% | -51.0% |
| Asmanex | – | – | – | – | $63.00M | $83.00M | $94.00M | – | – |
| Ganirelix Acetate Injection | – | – | – | $123.00M | $111.00M | $81.00M | $112.00M | – | – |
| Cerazette | – | – | – | – | $70.00M | $67.00M | $71.00M | – | – |
| Diprosone | – | – | – | – | $87.00M | $83.00M | $84.00M | – | – |
| Sinemet | – | – | – | – | $71.00M | $77.00M | $79.00M | – | – |
| Remeron | – | – | – | – | $66.00M | $64.00M | $82.00M | – | – |
| Zocor | – | – | – | – | $65.00M | $77.00M | $112.00M | – | – |
| Aybintio | – | $28.00M | $43.00M | $39.00M | $36.00M | $6.00M | – | – | – |
| Emgality/Rayvow | – | $107.00M | $0 | $0 | – | – | – | – | – |
| Other Non-Opioid Pain, Bone and Dermatology | – | $295.00M | $275.00M | $273.00M | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Intl | $4.61B | $4.83B | $4.79B | $4.74B | $4.92B | $5.12B | $5.76B | 74.2% | -4.5% |
| Europe and Canada | $1.62B | $1.76B | $1.67B | $1.63B | $1.74B | $1.73B | $1.89B | 26.0% | -8.2% |
| United States | $1.60B | $1.57B | $1.48B | $1.44B | $1.38B | $1.41B | $2.02B | 25.8% | +2.0% |
| Latin America, Middle East, Russia, and Africa | $1.07B | $1.03B | $965.00M | $895.00M | $841.00M | $857.00M | $923.00M | 17.2% | +3.7% |
| Asia Pacific and Japan | $1.00B | $1.05B | $1.13B | $1.14B | $1.17B | $1.54B | $1.79B | 16.1% | -4.8% |
| China | $829.00M | $847.00M | $864.00M | $917.00M | $933.00M | $873.00M | $1.03B | 13.3% | -2.1% |
| Other | $93.00M | $137.00M | $154.00M | $151.00M | $233.00M | $133.00M | $124.00M | 1.5% | -32.1% |
From the segment and revenue-disaggregation notes of Organon's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.